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Introduction: 
Vitronectin, or S-protein, is a regulatory glycoprotein found in the circulation and 
the extra-cellular matrix. It is known to be involved in a number of diverse physiological 
processes including the immune response, cell adhesion, blood coagulation, and 
fibrinolysis. There are few detailed studies involving the structure of vitronectin or how 
its structure mediates the regulatory properties associated with the protein. The 
remainder of this introduction is intended to relate what is known about the structural 
elements ofvitronectin and the role of the protein in vivo. 
Physiological Importance: 
The Immune Response-- Vitronectin was first isolated and characterized as a 
component in the complement cascade of the immune response (1). It was named S-
protein, soluble protein, on account of its ability to associate with the terminal complexes 
of the membrane attack complex and maintain these molecules in solution (1). 
Furthermore, vitronectin was found to associate with the C9 molecule, possibly through 
amino acid residues in the carboxyl terminal region of the protein, and prevent C9 
polymerization (2). It is the C9 polymer that inserts into the cell membrane and forms the 
lytic pore. Therefore, as it is understood, vitronectin prevents formation of the membrane 
attack complex (2). This anti-cytolitic property is believed to function as a safeguard 
mechanisn1, thus preventing injury to bystander cells (2). 
Cell Adhesion-- Vitronectin has also been associated with the property of cell 
adhesion and was subsequently characterized as "serum spreading factor (3,4)." 
Vitronectin was found to be the major serum component in tissue culture media that was 
responsible for cell adhesion (3,4). Vitronectin itself adheres to the surface of the culture 
dish through non-covalent interactions (5). Upon adhesion of vitronectin to the surface 
conformational changes occur (5). It is believed that the tripeptide RGD, which is 
recognized by the integrin class of cell receptors, becomes surface exposed during this 
conformational change allowing for cell attachment (5). 
Coagulation-- Vitronectin acts as a procoagulant through its neutralization of the 
activity of the anticoagulation drug heparin (6-10). Heparin accelerates the rate of 
deactivation of a coagulation protease, thrombin, by a serine protease inhibitor, 
antithrorrlbin, by supplying a surface on which these molecules can interact. The 
inactivation of thrombin by antithrombin is a diffusion limited process. Heparin, a 
glycosaminoglycan chain, binds both thrombin and antithrombin thus limiting their 
diffusion to one dimension, that of the heparin chain, instead of the three dimensions 
allowed in solution. Vitronectin destroys the catalytic property of heparin by binding to 
the heparin chain and preventing the movement of thrombin and antithrombin along the 
chain. The heparin binding site of vitronectin was localized to residues 340 through 379 
by cyanogen bromide digestion (7). 
Fibrinolysis-- Vitronectin is also known to be involved in the fibrinolytic 
pathway (11, 12-16). Fibrinolysis is the degradation of blood clots. Blood clots are 
formed when thrombin, the terminal protease of the coagulation cascade, cleaves soluble 
fibrinogen into insoluble molecules of fibrin. The blood clot is composed mainly of this 
fibrin. During fibrinolysis, plasmin digests the clot into small soluble fragments. 
Plasmin, however, must first be activated from its inactive form, plasminogen. 
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Plasminogen is activated by a group of serine proteases called plasminogen activators. 
Furthermore, these activator molecules can be inhibited by a molecule called 
plasminogen activator inhibitor type one (PAl -1). PAl -1 is in a class of molecules called 
serine protease inhibitors (SERPINS). These molecules have a common structure and 
mode of inactivation of their target proteases. SERPINS have a conserved "reactive 
loop" that contains the bond that is a pseudosubstrate for the serine proteases. Instead of 
cleaving this bond and releasing cleaved products, the protease forms a stable con1plex 
with the inhibitor. For the SERPIN to effectively block the proteolytic activity of the 
activators, however, the "reactive loop" must be surface exposed. In newly synthesized 
PAl -1 the "reactive loop" is surfaced exposed, but quickly self inserts into central beta 
sheet. Upon insertion of the "reactive loop" into the beta sheet, PAI-l looses its 
inhibitory activities and is said to become latent. Vitronectin plays an important anti-
fibrinolytic role in this process by binding to active P AI-I and preventing the insertion of 
the "reactive loop" into the core of the protein (17,18). 
Structural Elements: 
General Structure-- Mature vitronectin consists of 459 amino acids after the 
cleavage of a 19 amino acid signal sequence that instructs the liver cells, where 
vitronectin is synthesized, to secrete the protein into the circulation (19-23). The protein 
is glycosylated and highly charged containing a large number of arginines and lysines. 
Vitronectin also has nine tryptophan residues that can be used to monitor intrinsic protein 
fluorescence. In addition, vitronectin contains 14 cysteines of which the oxidation states 
are disputed. Vitronectin has a molecular weight of approximately 72 kilodaltons (24). 
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The protein is believed to exist largely in a "closed" of folded form in the circulation and 
as an "open" or unfolded form in the extra-cellular matrix. Moreover, vitronectin exists 
as a single chain form (72 kD) and as a cleaved two chain form (62 kD + 10 kD) that is 
disulfide cross-linked (19-23). 
Primary Sequence-- Although no crystal structure has been resolved for 
vitronectin much can be learned by analyzing the primary amino acid sequence of the 
protein. The 44 residues at the amino terminus of the protein comprise the 
"somatomedin B region." This region of vitronectin has sequence homology with 
another plasma protein, somatomedin B. Eight of the 14 cysteine residues in vitronectin 
are in this region. Through the homology with somatomedin B, each of these cysteines is 
believed to interact with one of the other seven cysteines contained within the region. 
This forms what is essentially a "disulfide knot" (25). Immediately adjacent to the 
"somatomedin B region" is the RGD tripeptide associated with the integrin class of cell 
receptors and the property of cell adhesion (5). Following the RGD sequence is an 
"acidic domain" that has been postulated to interact with a basic region in the carboxyl 
terminal region of the protein thus stabilizing the folded form of the vitronectin. This 
hypothesis, however, was proposed on the basis of sequence analysis without any 
experimental evidence (7). After the "acidic region" are two "hemopexin repeats." 
These regions have homology with the heme binding plasma protein, hemopexin (26). 
The second of these homologous repeats is imperfect, interrupted by the "heparin binding 
domain." The "heparin binding domain" is, of course, the region of the protein that binds 
to heparin. This highly basic region is proposed to interact with the "acidic region" that 
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is more amino terminally located (7). At the carboxyl terminal edge of the "heparin 
binding domain," after residue 379, is the endogenous cleavage site. Cleavage at this site, 
by a trypsin-like protease, produces the 62 kD and 10 kD two chain fonn of the molecule 
(27-28). 
Effects of Denaturation Upon Structure-- It has been suggested that denaturation 
of vitronectin, by heat or chemicals, results in the protein adopting a structure similar to 
that of the molecule when it is in the extra-cellular matrix (1-5). Some g~o.ups argue that 
vitronectin binds some ligands more tightly in this "open" confonnation (29-31), but this 
observation is debatable. Experimental evidence does suggest, however, that other 
processes do occur upon denaturation (32). One phenomenon is the failure of folding and 
unfolding curves to overlap as shown in the figure below. This historesis suggests that 
the pathways of unfolding and refolding are quite different. This observation agrees with 
the fact that upon removal of denaturant (or cooling if thermal denaturation) vitronectin 
has a tendency to irreversibly self-associate into multimers with a molecular weight of 
approximately 420 kilodaltons (24). 
Formation of Multimers 
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It has . also been observed that disulfide rearrangement occurs upon 
denaturation (32). The SDS polyacrylamide gel below (cartoon) shows that non-reduced 
native vitronectin migrates as a single band corresponding to both the single chain form 
and two chain disulfide linked form. Upon treatment of native vitronectin with a 
reducing agent, dithiothreotol (DTT), the disulfide bonds are disrupted. On account of 
the disruption of the disulfide bonds, including the one that links the 62 kD fragment and 
the 10 kD fragment of the two chain form, vitronectin migrates as a doublet 
;..,k ... 
corresponding to the single chain form and the 62 kD fragment of the two chain form. 
When vitronectin is denatured with urea, it migrates as a doublet even though no reducing 
agent has been added to the protein. This illustrates the disruption of the disulfide bond 
linking the large and small fragments of the two chain form, evidence that upon 
denaturation, disulfide bond rearrangement occurs. 
Native Vitronectin Denatured Vitronectin 
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Research Objective-- The primary objective of this study is to determine the 
oxidation states of the cysteine residues in native and chemically altered vitronectin. An 
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understanding of the oxidation states may be helpful in folding and binding studies, and 
elucidating the disulfide bonded structure of the protein, which has not yet been 
determined. A second goal is to attach a sulfhydryl specific fluorescent probe to the 
protein that may be useful for monitoring protein/protein and protein/ligand interactions. 
Materials and Methods: 
Vitronectin was purified by a modification of the original procedure of Dahlback 
and Podack, as described by Bittorf et al (33). The modifications of Bittorf et al. (33) 
include addition of dithionotrobenzoic acid (DTNB) during the preparation to block free 
sulfhydryls in the native protein that were originally reported in the Dahlback and Podack 
purification (34). Bittorf et al. indicate there is no clear evidence that DTNB is 
maintained on vitronectin throughout the preparation, since reduction of the purified 
protein sample with DTT was not accompanied by the release of the thionitrobenzoate 
anion (33). Purity of the protein was assessed by SDS-polyacrylamide gel 
electrophoresis in the presence of p-mercaptoethanol. A molecular weight of 72 kD and 
an extinction coefficient of 1.02 ml nlg-1 cm-I were used for the quantification of the final 
purified vitronectin (24). Multimeric vitronectin was prepared by treating the protein 
with 8 M urea at room temperature for two hours, followed by extensive dialysis into 
phosphate buffer (0.1 M sodium phosphate, 0.15 M sodium chloride, 1 mM EDTA, pH 
7.5) to remove the denaturant. 
Urea was purchased from ICN Biomedical. Acrylodan was a product of 
Molecular Probes Inc. Oxidized glutathione was from Calbiochem. Sephadex G-25 resin 
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was purchased from Pharmacia Biotech. Both DTNB and DTT were from Sigma. All 
other chemicals were of reagent grade quality. 
Cysteine Oxidation State Determination-- The number of reduced cysteines in 
vitronectin was determined using DTNB. The protein was denatured by adding 90 mg of 
solid urea to 0.200 ml of vitronectin (1 mg mrl) in 20 mM Tris, 20 mM NaCI, 1mM 
EDTA, pH 7.4, to give a final urea concentration of approximately 6 M. After 
dissolution of the denaturant, the reaction mixture was allowed to incubate at 25°C for 4 
hours. If reducing conditions were desired as well, 10 mM DTT was added to the 
reaction nlixture prior to incubation. If only reducing conditions were desired the 
denaturant was omitted. Following the incubation period, urea and DTT were removed 
by desalting the reaction mixture over a 5 ml Sephadex G-25 column equilibrated with 
0.1 M acetate, pH 6.0. Eluted vitronectin (0.725 ml) was treated with 0.250/0 SDS for 5 
minutes. The pH of the reaction mixture was then adjusted to 8.0 by the addition of 
0.235 ml 2 M ammonium phosphate, pH 9.25. The resulting free sulfhydryls were then 
reacted with 20 mM DTNB and the released thionitrobenzoate anion was quantitated at 
412 nm using an extinction coefficient of 1.14 x 104 M-l cm-l (35). Protein was 
quantitated by absorption at 280 nm prior to the addition of DTNB using an extinction 
coefficient of 1.02 ml mg-l cm-1 (24). Quantitation of reduced cysteines in native protein 
was determined in the same maimer, omitting the addition of urea and DTT to the 
incubation mixture. 
Fluorescent Labeling-- Labeling was performed by first partially reducing 
vitronectin with mildly reducing conditions and then reacting the reduced protein with 
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Acrylodan. Vitronectin was reduced by adding 0.2 nlM DTT to 0.200 ml of protein 
(1 mg mrl) in 20 nlM Tris, 20 nlM NaCI, 1 mM EDTA, pH 7.4. This reaction mixture 
was allowed to incubate for 30 minutes at 4°C. Following the incubation the reducing 
agent was removed by desalting the mixture over a 5 ml Sephadex G-25 column 
equilibrated with 0.1 M acetate, pH 6.0. The eluted protein (l ml) was then reacted with 
20 mM Acrylodan in 0.1 % dimethyl formamide for 24 hours at 4°C in the dark with 
gentle stirring. Unreacted probe was removed by centrifugation at 14,000 rpm for 10 
minutes followed by desalting over a 5 ml sephadex G-25 column equilibrated with 
20 mM Tris, 20 mM NaCI, 1 mM EDTA, pH 7.4. The success of the labeling was 
determined by analysis of an emission spectrum from 400 nm to 600 nm when excited at 
of 390 nm on a Perkin-Elmer LS-50B spectrofluorimeter. The stoichiometry of the 
labeling was resolved from the ratio of the protein, determined by Bradford assay (Bio-
Rad kit), to that of the bound probe, determined spectrophotometricly at 390 nm with an 
extinction coefficient of 2.00 x 104 M-1 cm-1 (36). 
Results: 
Cysteine Oxidation States-- Although vitronectin has been proposed to contain 
cysteines in both the reduced sulfhydryl state and the oxidized disulfide state, the number 
of free sulfhydryls has been disputed (33,34). The number of reduced cysteines in 
purified vitronectin were determined by treating the protein with DTNB under native and 
chemically altered conditions. Consistent with previous observations (33), native 
vitronectin was found to have essentially no free sulfhydryls (see table). The reduced 
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form, however, showed the presence of two free sulfhydryls. These results indicate that 
native vitronectin does indeed contain a mixture of reduced and oxidized cysteine 
residues. When vitronectin was treated with both denaturant and a strong oxidizing agent 
(oxidized glutathione), however, only 0.43 cysteines were found to be free. When 
vitronectin was treated with varying concentrations of reducing agent, the maxinlum 
number of sulfhydryls observed was 5.35, with a saturation at approximately 4 mM DTT 
(see graph). Multimeric protein was analyzed in a similar manner, but only under native 
and denaturing conditions. Multimeric protein was found to have 0.57 sulfhydryls when 
untreated and 1.18 when denatured. This result clearly indicates the difference in the 
oxidation states of cysteine residues in monomeric and multimeric vitronectin. 
Sample Number of free Cysteines 
Native Vitronectin None 
Reduced Vitronectin (10 mM DTT) 5.25 
Denatured Vitronectin 1.88 
Denatured Vitronectin with 10 mM 0.43 
Oxidized Glutathione 
Untreated Multimeric Vitronectin 0.57 
Denatured Multimeric Vitronectin 1.18 
Reduced and Denatured Vitronectin 12.10 
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The fully reduced and denatured vitronectin gave an average of 12.1 sulfhydryls per 
molecule of the protein, in close agreement with the 14 cysteines expected from the 
known sequence of the protein, validating the use ofDTNB for sulfhydryl quantitation. 
Varying Concentrations of 
Reducing Agents 
.10 .so 1.00 1.50 2.00 2.50 
Concmtration of Reducin& Agent (mM) 
Fluorescent Labeling-- Acrylodan was used for labeling on account of its 
sulfhydryl specificity and sensitivity towards environmental polarity (36). When the 
probe was reacted with untreated vitronectin no labeling was observed. This result was 
not surprising since it had been shown ,by the DTNB studies that native vitronectin 
contains no surface exposed free sulfhydryl groups. When vitronectin, however, was 
reduced with 0.2 mM DTT prior to the addition of the Acrylodan, two molecules of probe 
were incorporated per molecule of the protein. 
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Discussion: 
Cysteine Oxidation States-- It is apparent from the native and denaturing DTNB 
reactions that vitronectin does indeed contain cysteines that are a mixture of reduced and 
oxidized forms as suggested in the literature (34). The native protein, as purified 
following the Bittorf et al. protocol (33), has no free sulfhydryls that are surface exposed, 
but does contain two that are buried within the core of the protein. These two sulfhydryls 
become surface exposed, and thus available for reaction with DTNB, only after chemical 
denaturant is added. It is presumably these two reduced cysteines that initiate the 
disulfide rearrangement upon denaturation as previously mentioned in the introduction of 
this paper. These cysteines are sequestered within the core of the protein under native 
conditions, but when the protein is denatured, they become labile. With the increased 
motility permitted by denaturation, the free sulfhydryls are able to move close enough to 
existing disulfides that a free sulfhydryl can attack a disulfide bond. This results in the 
previously reduced cysteine becoming oxidized, forming a new disulfide bond, and the 
disnlption of the formerly existing disulfide. The severance of the disulfide also 
generates a new reduced cysteine that can go through the same attacking process or 
remain reduced. It has been reported that disulfide rearrangement can be prevented by 
blocking the free sulfhydryls contained within the core of vitronectin (31). The results 
obtained by reacting DruB with protein that had been denatured in the presence of 
oxidized glutathione found that only 0.43 cysteines were reduced. This agrees with the 
observations made by analyzing SDS-polyacrylamide gels that the addition of oxidizing 
agent prevents disulfide rearrangement. 
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It was noted earlier that reduction of cysteines with increasing concentrations of 
reducing agent saturates at about 4 mM DTT. Only slightly over five cysteines could be 
reduced regardless of the concentration of the reducing agent. Vitronectin contains an 
even number of total cysteines and an even number of reduced cysteines in its native 
conformation. It may seem confusing then, that an odd number of cysteines are produced 
upon reduction, especially if one realizes that when one cysteine in a disulfide is reduced 
the second cysteine in the disulfide must be reduced as well. One explanation for the 
apparent reduction of an odd number of cysteines is a mixture of molecular species. It is 
possible that the reduced vitronectin existed as two discrete populations, one population 
with four free sulfhydryls and a second population with six free sulfhydryls. These two 
populations, if they contained an equal or slightly skewed distribution of molecules, 
would produce an average of five reduced cysteines when quantitated by the DTNB 
reaction. A second explanation would be that five is the correct value. It is possible that 
one of the two sulfhydryls buried within the protein became exposed when two disulfides 
on the surface were reduced. This would allow the sulfhydryl that was buried in the 
native protein to react with the DTNB. A final explanation for the apparent reduction of 
an odd number of cysteines is that of experimental error. It is possible that the 5.25 
reduced cysteines should have been six, or even four. The DTNB reaction, although very 
precise, could simply not have been entirely accurate. 
A final observation from the DTNB data regards the cysteine oxidation states of 
the monomer versus the multi mer. It was found that the untreated monomer contains 
essentially no free sulfhydryls while the denatured monomer contains about two reduced 
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cysteines. The untreated multimer, however, contained about 0.6 and the denatured 
multimer about 1.2 free sulfhydryls per monomeric subunit of the multimer. Although 
nothing can be postulated about which cysteine residues are differentially reduced in 
these two forms of the protein, this data does help reinforce the observations that the 
monomer and the individual subunits of the multimer are different species (24,31). 
Fluorescent Labeling of Vitronectin-- Acrylodan was used as the fluorescent 
probe in the labeling reactions due to its sulfhydryl specificity and its environmental 
~, . 
sensitivity (36). Acrylodan forms a thio-ether with the protein through a carbonyl group 
that stems from the central acryloyl rings. The probe is sensitive to the polarity of its 
environment, showing a blue shift in the emission spectrum when in hydrophobic 
environments and a red shift in hydrophilic environments. This may allow the probe to 
be a useful tool in folding and binding studies. 
When the probe was reacted with the protein and excited with 390 nm light, the 
emission spectrunl from 400 nm to 600 nm showed an increase in fluorescent intensity 
and an approximate 20 nm blue shift when compared to the same spectrum obtained from 
free probe (see graph). The labeling under mildly reducing conditions incorporated two 
molecules of the probe per molecule of vitronectin in agreement with the observation of 
two reduced cysteines under the same reaction conditions. 
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Conclusion: 
Oxidation States of the Cysteines-- The DTNB reactions were useful in 
determining the number of free sulfhydryls in native and chemically altered vitronectin. 
It was found that native monomeric vitronectin contained no free surface exposed 
sulfhydryls, but had two free sulfhydryls buried within the core of the protein. These 
sulfhydryls become exposed upon denaturation and initiate the sulfhydryl rearrangement 
that is observed upon denaturation. These sulfhydryls, however, can be blocked by the 
addition of oxidizing agent and the disulfide rearrangement prevented. 
DTNB experiments were also used to analyze and compare the oxidation states of 
the cysteines in monomeric and multimeric vitronectin. It was found that the oxidation 
states of the two proteins consistently differed under denaturing and non-denaturing 
conditions This is in agreement with the observation that the monomeric unit in these 
two forms of the protein are structurally different (24,31). 
Fluorescent Labeling-- It was found that vitronectin could be labeled with a 
sulfhydryl specific probe, Acrylodan, only after the protein was partially reduced. The 
reduction of two cysteines allowed for the incorporation of two molecules of probe. The 
bound probe showed an increase in fluorescent intensity with a 20 nm blue shift in probe 
emission wavelength. 
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